Bruno Pougault: Oral Anticoagulants Are Essential, But Not a ‘Fix-All’
Bruno Pougault, Global Marketing Hemostasis Product Manager at HORIBA, shared on LinkedIn about a recent article by Eva Soler-Espejo et al, published in JAHA:
”Oral anticoagulants: Essential, but not a ‘fix-all’.
A huge thank you to the authors of this recent study in JAHA (DOI: 10.1161/JAHA.125.046694) for highlighting the reality of residual risk.
Even with optimal treatment, the risk of stroke in AFib patients persists.
This research is a vital reminder that we must look beyond the prescription: managing comorbidities and lifestyle remains just as crucial as the medication itself.
Great work by the team for pushing the boundaries of comprehensive cardiovascular care!”
Title: Atherogenic Index of Plasma and Residual Risk in Anticoagulated Patients With Atrial Fibrillation: The Prospective Murcia Atrial Fibrillation Project III Cohort
Authors: Eva Soler-Espejo, Yang Chen, José M. Rivera-Caravaca, María P. Ramos-Bratos, Francisco Marín, Vanessa Roldán, Gregory Y. H. Lip
Read the Full Article on JAHA
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 14, 2026, 11:40Liz Devlin: When HHT Affects More Than What We Can See
-
Aug 14, 2026, 11:29Archil Jaliashvili: Can Italy Reduce Its Dependence on Imported Plasma
-
Aug 14, 2026, 11:21Osama Alabdi: Never Ignore a Weak Reaction in the Blood Bank
-
Aug 14, 2026, 11:14Yohan Santin: How Lysosomal Dysfunction Drives Cardiac Aging
-
Aug 14, 2026, 11:06Nicolas Schommer: When Neutrophils Turn Metabolic Stress Into Organ Injury
-
Aug 14, 2026, 10:49Pablo Corral: Can One Infusion Lower LDL for Years
-
Aug 14, 2026, 08:17Maha Othman: Celebrating Research and Collaboration at the Sinclair Cancer Research Institute 2026 Annual Retreat
-
Aug 14, 2026, 06:26Delivering Gene Therapy in Hemophilia – ISTH
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children